[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409823":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":40,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Hospital Universitario La Fe","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Liver transplanted patients",null,[12],"Procedure: Liver transplantation",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","Liver transplantation","Chemotherapy and liver transplantation",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Eva M Montalvá, PhD","CONTACT","+34961245858","montalva.oron@gmail.com",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Eva M Montalvá","RECRUITING","Valencia","46026","Spain",{"type":33,"coordinates":34},"Point",[35,36],-0.37966,39.47391,{"lat":36,"lon":35},[39],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Eva M. Montalvá","Hepatobiliarypancreatic and Transplant Surgeon","100409823",false,"NCT04616495","Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases","TRASMETIR","Inclusion Criteria:\n\n* ≥ 18 and ≤ years\n* Good performance status, ECOG 0 or 1\n* Resected adenocarcinoma in colon or rectum (R0 resection)\n* Unresectable liver metastases\n* No extrahepatic disease\n* Normal blood tests\n* Response to ≤ 2 lines of chemotherapy (RECIST criteria)\n* ≥ 1 year period since diagnosis of colorectal cancer to enrolment in liver transplant waiting list\n* Signed informed consent\n\nExclusion Criteria:\n\n* Body mass index ≥ 30\n* Positive HIV or HCV\n* Pregnancy at the time of inclusion\n* BRAF mutated status\n* Deterioration of general condition (10% weight loss in the prior 6 months)\n* Other malignancy with disease free survival \\\u003C 5 years\n* Concomitant or prior extrahepatic metastases (histologically or radiologically proved), even if surgically resected.\n* Palliative resection of primary colorectal adenocarcinoma\n* Liver metastases size \\> 5 cm (in the last imaging technique)\n* CEA \\> 80 ng\u002Fml (at time of enrolment in waiting list)\n* No neoadjuvant chemotherapy treatment\n* General contraindication to liver transplantation","ALL","18 Years","65 Years",{"count":54,"type":55},30,"ESTIMATED","5 Years","OBSERVATIONAL","Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.",[60,61,62],"Colorectal Cancer","Metastatic Liver Cancer","Liver Metastases","2023-09-21",{"date":65,"type":66},"2023-09-22","ACTUAL",{"date":68,"type":66},"2021-09-01",{"date":70,"type":55},"2028-09",{"name":5,"class":6},1]